Trends of 5-Aminosalicylate Medication Use in Patients With Crohn Disease | Zendy

Mohamed Noureldin | Zendy; Shirley CohenMekelburg | Zendy; Asadullah Mahmood | Zendy; Ryan W. Stidham | Zendy; Peter Higgins | Zendy; Shail M. Govani | Zendy; Amar R. Deshpande | Zendy; Akbar K. Waljee | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Trends of 5-Aminosalicylate Medication Use in Patients With Crohn Disease

Author(s) -

Mohamed Noureldin,

Shirley CohenMekelburg,

Asadullah Mahmood,

Ryan W. Stidham,

Peter Higgins,

Shail M. Govani,

Amar R. Deshpande,

Akbar K. Waljee

Publication year - 2020

Publication title -

inflammatory bowel diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.932

H-Index - 146

eISSN - 1536-4844

pISSN - 1078-0998

DOI - 10.1093/ibd/izaa127

Subject(s) - medical prescription , medicine , inflammatory bowel disease , sulfasalazine , ulcerative colitis , health plan , retrospective cohort study , disease , residence , logistic regression , pediatrics , health care , demography , pharmacology , sociology , economics , economic growth

5-aminosalicylate (5-ASA) medications have a long history of use for the treatment of inflammatory bowel disease and continue to be widely prescribed today. The effectiveness of 5-ASAs in ulcerative colitis is clear; however, studies have shown little benefit for induction or maintenance treatment of Crohn disease (CD). We aimed to quantify usage and examine trends in 5-ASA prescription rates in patients with CD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research